SE370449B
(pt)
|
1970-08-29 |
1974-10-14 |
Philips Nv |
|
JPS5824836B2
(ja)
|
1974-10-14 |
1983-05-24 |
ノウミボウサイコウギヨウ カブシキガイシヤ |
カサイナドノツウホウソウチ
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
ES521371A0
(es)
|
1982-04-12 |
1984-05-16 |
Hybritech Inc |
Un procedimiento para la purificacion de un anticuerpo.
|
US4689299A
(en)
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
JPS6350741A
(ja)
|
1986-08-20 |
1988-03-03 |
Nippon Tectron Co Ltd |
蛍光偏光分析装置
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5322678A
(en)
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
CA2006684C
(en)
|
1988-12-30 |
1996-12-17 |
Charles T. Esmon |
Monoclonal antibody against protein c
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインcの分離方法
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1991012023A2
(en)
|
1990-02-16 |
1991-08-22 |
Boston Biomedical Research Institute |
Hybrid reagents capable of selectively releasing molecules into cells
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
ES2134212T3
(es)
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
CA2149329C
(en)
|
1992-11-13 |
2008-07-15 |
Darrell R. Anderson |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
WO1994029471A1
(en)
|
1993-06-10 |
1994-12-22 |
Genetic Therapy, Inc. |
Adenoviral vectors for treatment of hemophilia
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
EP2077120A3
(en)
|
1994-10-07 |
2009-07-15 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient
|
DE4436561C1
(de)
|
1994-10-13 |
1996-03-14 |
Deutsche Spezialglas Ag |
Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
|
CZ298790B6
(cs)
|
1994-10-21 |
2008-01-30 |
Kishimoto@Tadamitsu |
Farmaceutický prípravek pro prevenci nebo lécení kachexie
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US6485943B2
(en)
|
1995-01-17 |
2002-11-26 |
The University Of Chicago |
Method for altering antibody light chain interactions
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
CA2259163C
(en)
|
1996-07-19 |
2004-07-06 |
Amgen Inc. |
Nt-3 and bdnf analogs having improved circulating life and/or absorption
|
US5990286A
(en)
|
1996-12-18 |
1999-11-23 |
Techniclone, Inc. |
Antibodies with reduced net positive charge
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
HU226175B1
(en)
|
1997-04-17 |
2008-06-30 |
Amgen Inc |
Human ob protein suspension, process for producing thereof and use for production of pharmaceutical composition
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
DE69830315T2
(de)
|
1997-06-24 |
2006-02-02 |
Genentech Inc., San Francisco |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
RU2221809C2
(ru)
|
1997-10-03 |
2004-01-20 |
Тугаи Сейяку Кабусики Кайся |
Способ получения природного гуманизированного антитела
|
ATE419009T1
(de)
|
1997-10-31 |
2009-01-15 |
Genentech Inc |
Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
ATE531812T1
(de)
|
1997-12-05 |
2011-11-15 |
Scripps Research Inst |
Humanisierung von nager-antikörpern
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
SK14812000A3
(sk)
|
1998-04-03 |
2001-08-06 |
Chugai Seiyaku Kabushiki Kaisha |
Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
MXPA01005515A
(es)
|
1998-12-01 |
2003-07-14 |
Protein Design Labs Inc |
Anticuerpos humanizados para gamma-interferon.
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
AU782626B2
(en)
|
1999-10-04 |
2005-08-18 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PRODUCING A POLYPEPTIDE
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
AU784983B2
(en)
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
JP2004511426A
(ja)
|
2000-05-03 |
2004-04-15 |
ミュンヘン バイオテク アーゲー |
活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CA2424602C
(en)
|
2000-10-06 |
2012-09-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-producing cell
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP2281840A3
(en)
|
2000-10-10 |
2012-05-23 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
YU80903A
(sh)
|
2001-04-13 |
2006-05-25 |
Biogen Inc. |
Antitela vla-1
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
ATE407204T1
(de)
|
2001-06-22 |
2008-09-15 |
Chugai Pharmaceutical Co Ltd |
Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
CN100391537C
(zh)
|
2001-08-17 |
2008-06-04 |
建南德克公司 |
结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
|
US20030049203A1
(en)
|
2001-08-31 |
2003-03-13 |
Elmaleh David R. |
Targeted nucleic acid constructs and uses related thereto
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
CN100374457C
(zh)
|
2001-11-14 |
2008-03-12 |
森托科尔公司 |
抗il-6抗体、组合物、方法和用途
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US6684637B2
(en)
|
2002-01-25 |
2004-02-03 |
Sunpower, Inc. |
Parallel slot heat exchanger
|
EP1573002A4
(en)
|
2002-02-11 |
2008-07-16 |
Genentech Inc |
ANTIBODY VARIANTS WITH ACCELERATED ANTIGEN ASSOCIATED SPEEDS
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
WO2003074679A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
EP1513879B1
(en)
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003256266A1
(en)
|
2002-06-12 |
2003-12-31 |
Genencor International, Inc. |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
DK1512015T3
(da)
|
2002-06-12 |
2009-07-06 |
Genencor Int |
Fremgangsmåder til forbedring af bindingsegenskaber hos et molekyle
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
CA2492524A1
(en)
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2515081A1
(en)
|
2003-02-07 |
2004-08-19 |
Protein Design Labs, Inc. |
Amphiregulin antibodies and their use to treat cancer and psoriasis
|
EP1601697B1
(en)
|
2003-02-28 |
2007-05-30 |
Lonza Biologics plc |
Antibody purification by Protein A and ion exchange chromatography
|
RU2399381C2
(ru)
|
2003-02-28 |
2010-09-20 |
Антидженикс Инк. |
Использование лектинов для активации олигомеризации гликопротеидов и антигенных молекул
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
KR20060027801A
(ko)
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
B 세포 장애에 대한 조합 요법
|
AU2004273791A1
(en)
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US7820800B2
(en)
|
2003-11-05 |
2010-10-26 |
Ares Trading S.A. |
Process for the purification of IL-18 binding protein
|
EA036531B1
(ru)
|
2003-11-05 |
2020-11-19 |
Роше Гликарт Аг |
Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
CA2546054C
(en)
|
2003-12-10 |
2014-05-13 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
SV2006001990A
(es)
|
2004-01-09 |
2006-01-30 |
Pfizer |
Anticuerpos contra madcam
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
DE602005020743D1
(de)
|
2004-02-11 |
2010-06-02 |
Warner Lambert Co |
Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
WO2005112564A2
(en)
|
2004-04-15 |
2005-12-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Germline and sequence variants of humanized antibodies and methods of making and using them
|
KR100620554B1
(ko)
|
2004-06-05 |
2006-09-06 |
한국생명공학연구원 |
Tag-72에 대한 인간화 항체
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
CA2568952C
(en)
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1773391A4
(en)
|
2004-06-25 |
2009-01-21 |
Medimmune Inc |
INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
EA012464B1
(ru)
|
2004-08-04 |
2009-10-30 |
Эпплайд Молекьюлар Эволюшн, Инк. |
Антитело против cd20 и его применение
|
MX2007002883A
(es)
|
2004-09-13 |
2007-06-15 |
Macrogenics Inc |
Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
|
EP1799718A1
(en)
|
2004-09-14 |
2007-06-27 |
National Institute for Biological Standards and Control (NIBSC) |
Vaccine
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
EP1791565B1
(en)
|
2004-09-23 |
2016-04-20 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
ATE461211T1
(de)
|
2004-12-23 |
2010-04-15 |
Novo Nordisk As |
Liganden mit antikörperbindender affinität
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
US10011858B2
(en)
|
2005-03-31 |
2018-07-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
DK2824183T3
(da)
|
2005-04-08 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af bispecifikke antistoffer
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
|
ES2534760T3
(es)
|
2005-08-19 |
2015-04-28 |
Wyeth Llc |
Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
WO2007060411A1
(en)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
|
CA2631212A1
(en)
|
2005-11-28 |
2007-07-05 |
Medimmune, Llc |
Antagonists of hmgb1 and/or rage and methods of use thereof
|
US20070237764A1
(en)
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
AU2006326283B2
(en)
*
|
2005-12-12 |
2012-01-19 |
Ac Immune S.A. |
Therapeutic vaccine
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
RU2445975C2
(ru)
|
2006-03-02 |
2012-03-27 |
Алексион Фармасьютикалз, Инк. |
Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
|
PL2596807T3
(pl)
|
2006-03-08 |
2016-06-30 |
Archemix Llc |
Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
|
EP4316465A3
(en)
|
2006-03-15 |
2024-04-24 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
CN101500608A
(zh)
|
2006-06-08 |
2009-08-05 |
中外制药株式会社 |
炎性疾病的预防或治疗药
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
CA3163418A1
(en)
|
2006-10-06 |
2008-05-22 |
Jeffrey S. Isenberg |
Prevention of tissue ischemia, related methods and compositions
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
JP2010521194A
(ja)
*
|
2007-03-22 |
2010-06-24 |
ノバルティス アーゲー |
C5抗原およびその使用
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
BRPI0813954A2
(pt)
|
2007-06-29 |
2020-10-06 |
Quest Diagnostics Investments Incorporated |
análise de aminoácidos no fluido do corpo através de cromatografia líquida-espectometria de massa
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
CL2008002886A1
(es)
|
2007-09-26 |
2009-12-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
|
PE20140132A1
(es)
|
2007-09-26 |
2014-02-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de il-6
|
AU2008305851B2
(en)
|
2007-09-28 |
2014-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
KR102469853B1
(ko)
|
2008-04-11 |
2022-11-22 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
WO2009152354A1
(en)
|
2008-06-14 |
2009-12-17 |
Vytronus, Inc. |
System and method for delivering energy to tissue
|
EA027575B1
(ru)
|
2008-08-05 |
2017-08-31 |
Новартис Аг |
Антитело или его антигенсвязывающий фрагмент, связывающий человеческий белок с5, содержащая их композиция, нуклеиновая кислота, кодирующая антитело или его антигенсвязывающий фрагмент, содержащие эту кислоту вектор и клетка-хозяин и применение антитела или его антигенсвязывающего фрагмента
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
EP2894165B1
(en)
|
2008-11-10 |
2023-01-04 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
WO2010098863A1
(en)
|
2009-02-26 |
2010-09-02 |
Lpath, Inc. |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
CN102597005A
(zh)
|
2009-06-23 |
2012-07-18 |
阿雷克森制药公司 |
与补体蛋白质结合的双特异性抗体
|
CN101875696B
(zh)
*
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
EP2327725A1
(en)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Anti-C5a binding moieties with high blocking activity
|
WO2011094593A2
(en)
|
2010-01-28 |
2011-08-04 |
Ab Biosciences, Inc. |
Novel lowered affinity antibodies and methods of marking the same
|
AU2011223866B2
(en)
|
2010-03-01 |
2015-05-21 |
Alexion Pharmaceuticals Inc. |
Methods and compositions for treating Degos' disease
|
TW201206466A
(en)
*
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
WO2011111007A2
(en)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
CN103108885A
(zh)
|
2010-04-30 |
2013-05-15 |
阿雷克森制药公司 |
在人中具有降低的免疫原性的抗体
|
AU2011337704B2
(en)
|
2010-11-30 |
2017-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
CA2822288A1
(en)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Anti-c5/c5a/c5adesr antibodies and fragments
|
MX352889B
(es)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo de fc especifico para fcyriib.
|
SG195072A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Cd3-binding molecules capable of binding to human and non-human cd3
|
US8961981B2
(en)
*
|
2011-06-20 |
2015-02-24 |
Saint Louis University |
Targeting the neuromuscular junction for treatment
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
JP6138108B2
(ja)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
SI2825037T1
(sl)
|
2012-03-16 |
2019-08-30 |
Regeneron Pharmaceuticals, Inc. |
Glodavci, ki izražajo PH občutljiva zaporedja imunoglobulina
|
CN107827979A
(zh)
|
2012-03-16 |
2018-03-23 |
瑞泽恩制药公司 |
组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物
|
HUE037613T2
(hu)
*
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
WO2014028354A1
(en)
|
2012-08-13 |
2014-02-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
TW201418707A
(zh)
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
CA2899589C
(en)
*
|
2013-01-31 |
2022-02-22 |
Seoul National University R & Db Foundation |
C5 antibody and method for preventing and treating complement-related diseases
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
EP2968985A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
ES2768648T3
(es)
|
2013-03-29 |
2020-06-23 |
Alexion Pharma Inc |
Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
US20160184391A1
(en)
|
2013-08-16 |
2016-06-30 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
JP6382641B2
(ja)
|
2013-09-11 |
2018-08-29 |
株式会社東芝 |
非水電解質電池及び非水電解質電池の製造方法
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
JP2016024424A
(ja)
|
2014-07-24 |
2016-02-08 |
株式会社リコー |
情報処理システム、情報処理装置、情報処理方法、及びプログラム
|
RU2746356C2
(ru)
|
2014-12-19 |
2021-04-12 |
Чугаи Сейяку Кабусики Кайся |
Антитела к с5 и способы их применения
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
KR20170110129A
(ko)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
WO2016160756A2
(en)
|
2015-03-31 |
2016-10-06 |
Alexion Pharmaceuticlas, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents
|
WO2016178980A1
(en)
|
2015-05-01 |
2016-11-10 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
|
US20180142010A1
(en)
|
2015-06-26 |
2018-05-24 |
Alexion Pharmaceuticals, Inc. |
Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
PL3390442T3
(pl)
|
2015-12-18 |
2024-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała anty-c5 i sposoby ich stosowania
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
US20190023775A1
(en)
|
2016-01-11 |
2019-01-24 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
EP3408291A1
(en)
|
2016-01-25 |
2018-12-05 |
Shire Human Genetic Therapies, Inc. |
Anti-c5 antibodies with enhanced ph switch
|
US10633434B2
(en)
|
2016-06-14 |
2020-04-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-C5 antibodies
|
MY187848A
(en)
|
2016-06-17 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
EP4223774A3
(en)
|
2017-01-31 |
2023-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
EP3595720A4
(en)
|
2017-03-14 |
2021-05-26 |
Five Prime Therapeutics, Inc. |
ANTIBODIES BINDING TO VISTA AT AN ACID PH
|
KR20190129925A
(ko)
|
2017-03-16 |
2019-11-20 |
메디뮨 리미티드 |
항-par2 항체 및 그의 용도
|
CA3058023A1
(en)
|
2017-04-03 |
2018-10-11 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
JP2021501134A
(ja)
|
2017-10-26 |
2021-01-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
|
CN111683672A
(zh)
|
2017-12-04 |
2020-09-18 |
Ra制药公司 |
补体活性调节剂
|
KR20210038697A
(ko)
|
2018-08-01 |
2021-04-07 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|